Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$513M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$412M |
| 3 |
Meta Platforms (Facebook)
META
|
+$354M |
| 4 |
ServiceNow
NOW
|
+$262M |
| 5 |
American Airlines Group
AAL
|
+$259M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$571M |
| 2 |
Apple
AAPL
|
+$571M |
| 3 |
Netflix
NFLX
|
+$388M |
| 4 |
NVIDIA
NVDA
|
+$313M |
| 5 |
TSMC
TSM
|
+$211M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.32% |
| 2 | Healthcare | 15.28% |
| 3 | Consumer Discretionary | 11.85% |
| 4 | Financials | 11.11% |
| 5 | Industrials | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
Pluri
PLUR
$19.5M
| $133K | ﹤0.01% |
30,925
-3,100
| -9% | -$13.8K |
|
|
NXTS
3152
Nexentis Technologies
NXTS
$2.8M
| $129K | ﹤0.01% |
+2,206
| New | +$427K |
|
3153
SIFCO Industries
SIF
$177M
| $129K | ﹤0.01% |
46,696
-6,038
| -11% | -$20.1K |
|
3154
Xilio Therapeutics
XLO
$61M
| $129K | ﹤0.01% |
12,693
-8,494
| -40% | -$107K |
|
|
UCL
3155
uCloudlink Group
UCL
$27.5M
| $128K | ﹤0.01% |
104,005
+49,200
| +90% | +$65.6K |
|
3156
Bolt Biotherapeutics
BOLT
$7.44M
| $126K | ﹤0.01% |
15,707
+605
| +4% | +$5.81K |
|
3157
UNIFI
UFI
$128M
| $126K | ﹤0.01% |
26,100
-18,900
| -42% | -$106K |
|
3158
Black Diamond Therapeutics
BDTX
$110M
| $124K | ﹤0.01% |
79,900
-824,100
| -91% | -$1.73M |
|
3159
NanoViricides
NNVC
$35.7M
| $124K | ﹤0.01% |
105,800
-39,900
| -27% | -$50.6K |
|
3160
SurgePays
SURG
$8.16M
| $122K | ﹤0.01% |
59,000
+9,600
| +19% | +$14.2K |
|
3161
ClearOne Inc
CLRO
$26.2M
| $122K | ﹤0.01% |
14,528
-4,089
| -22% | -$39K |
|
|
IRD
3162
Opus Genetics
IRD
$307M
| $121K | ﹤0.01% |
123,709
-21,800
| -15% | -$24.4K |
|
|
PRPH
3163
DELISTED
ProPhase Labs
PRPH
| $121K | ﹤0.01% |
29,981
+1,332
| +5% | +$6.11K |
|
3164
Anavex Life Sciences
AVXL
$304M
| $120K | ﹤0.01% |
14,000
-199,200
| -93% | -$1.88M |
|
3165
Lipocine
LPCN
$17.6M
| $119K | ﹤0.01% |
37,510
+1,478
| +4% | +$5.72K |
|
3166
Greenwich LifeSciences
GLSI
$209M
| $119K | ﹤0.01% |
12,500
-10,200
| -45% | -$124K |
|
3167
Luxfer Holdings
LXFR
$457M
| $119K | ﹤0.01% |
+10,000
| New | +$131K |
|
3168
American Vanguard Corp
AVD
$73.5M
| $117K | ﹤0.01% |
26,700
-64,915
| -71% | -$331K |
|
3169
Sono-Tek
SOTK
$85.2M
| $117K | ﹤0.01% |
32,200
-1,300
| -4% | -$4.98K |
|
|
OPTN
3170
DELISTED
OptiNose
OPTN
| $117K | ﹤0.01% |
12,748
| – | – |
|
3171
Comtech Telecommunications
CMTL
$51.5M
| $117K | ﹤0.01% |
73,000
-1,003
| -1% | -$2.3K |
|
3172
Siebert Financial
SIEB
$68M
| $117K | ﹤0.01% |
38,800
-200
| -0.5% | -$552 |
|
|
NURO
3173
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $117K | ﹤0.01% |
26,385
+14,825
| +128% | +$63.6K |
|
3174
Yunhong Green CTI Ltd
YHGJ
$8.17M
| $115K | ﹤0.01% |
11,367
-260
| -2% | -$1.9K |
|
3175
Gogoro
GGR
$53M
| $114K | ﹤0.01% |
21,055
-6,744
| -24% | -$56.9K |
|
Similar funds
Renaissance Technologies's Q1 2025 Portfolio in Review
As of Q1 2025, Renaissance Technologies held 3,989 positions worth $66.1B, down 2.2% from $67.6B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2025 filing shows 456 new, 1,472 increased, 1,441 reduced and 583 closed positions. Its largest new stake was ServiceNow: 1,361,505 shares worth $217M. The largest sale was Palantir, an estimated $571M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q1 2025 buy was ServiceNow: 1,361,505 shares worth $217M.
- Renaissance Technologies added most to Broadcom in Q1 2025, an estimated $513M increase.
- Renaissance Technologies's biggest Q1 2025 reduction was Palantir, cutting an estimated $571M.
- Renaissance Technologies fully exited Nike in Q1 2025, selling an estimated $197M.
- Renaissance Technologies's ten largest holdings make up 11% of its $66.1B portfolio in Q1 2025.
- Renaissance Technologies opened 456 new positions and closed 583 in Q1 2025.
- Renaissance Technologies's portfolio value fell 2.2% quarter-over-quarter to $66.1B.
Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.